Health Care [ 9/12 ] | Pharmaceuticals [ 54/73 ]
NASDAQ | Common Stock
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction.
In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -0.64 Increased by +36.63% | -0.63 Decreased by -1.59% |
| Feb 25, 25 | -0.60 Increased by +54.20% | -0.82 Increased by +26.44% |
| Nov 7, 24 | -0.61 Increased by +52.34% | -0.94 Increased by +35.11% |
| Aug 8, 24 | -0.88 Increased by +24.79% | -0.92 Increased by +4.35% |
| May 8, 24 | -1.01 Decreased by -14.77% | -1.20 Increased by +15.83% |
| Feb 27, 24 | -1.31 Decreased by -167.35% | -1.36 Increased by +3.68% |
| Nov 9, 23 | -1.28 Decreased by -52.38% | -1.37 Increased by +6.57% |
| Aug 10, 23 | -1.17 Decreased by -387.50% | -1.08 Decreased by -8.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 78.33 M Increased by +183.68% | -25.12 M Increased by +29.70% | Decreased by -32.07% Increased by +75.22% |
| Dec 31, 24 | 66.41 M Increased by +407.86% | -23.11 M Increased by +44.84% | Decreased by -34.80% Increased by +89.14% |
| Sep 30, 24 | 48.12 M Increased by +2.47 K% | -23.42 M Increased by +40.18% | Decreased by -48.67% Increased by +97.67% |
| Jun 30, 24 | 40.81 M Increased by +167.15% | -33.29 M Decreased by -5.94% | Decreased by -81.57% Increased by +60.35% |
| Mar 31, 24 | 27.61 M Increased by +1.00 K% | -35.73 M Decreased by -63.26% | Decreased by -129.39% Increased by +85.22% |
| Dec 31, 23 | 13.08 M Increased by +30.76% | -41.90 M Decreased by -220.40% | Decreased by -320.45% Decreased by -145.03% |
| Sep 30, 23 | 1.87 M Increased by +N/A% | -39.15 M Decreased by -73.91% | Decreased by -2.09 K% Decreased by N/A% |
| Jun 30, 23 | 15.28 M Increased by 0.00% | -31.42 M Decreased by -447.17% | Decreased by -205.69% Decreased by -447.17% |